AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer
Joining teams and expertise, the two companies will make their mark on a new era of pancreatic cancer treatment, reaffirming their shared commitment to improving people’s lives.
BARCELONA, 16th July 2024.- AGC Pharma Chemicals, an international Contract Development and Manufacturing Organization (CDMO) company based in Spain (Barcelona, Malgrat de Mar) and Japan that develops and manufactures active pharmaceutical ingredients (APIs) and intermediates, and AbilityPharma, a pioneering biotech company based in Catalonia, have announced a strategic collaboration for the development of an API for the treatment of pancreatic cancer, ABTL0812, currently in clinical trials.
AGC Pharma Chemicals brings extensive experience and resources to the project. As a CDMO, it has demonstrated its capabilities in familiarization, process optimization and scale-up to develop and produce this API from the clinical phase to its commercialization stage. Pioneers in scaling up processes in the production of APIs for drugs from grams to tons, AGC Pharma Chemicals will use its GMP Kilo lab and GMP production line for this project, ensuring the highest quality standards necessary.
ABTL0812 represents a significant advance in the treatment of pancreatic cancer, an orphan disease in urgent need of effective therapies. The product enhances the effects of several types of chemotherapy without increasing toxicity and has shown promising results in clinical trials, including an increased overall response rate and progression-free survival. The collaboration with AGC Pharma Chemicals will enable AbilityPharma to advance the implementation of this innovative therapy from the laboratory to patients around the world.
AbilityPharma, with a focus on such innovative oncology therapies, recognizes the potential of this collaboration. AGC has high pharmaceutical standards, demonstrated in the results of quality inspections (more than 20 years with no FDA 483 observations, no critical or major findings), which is a valuable asset for the ABTL0812 project. In addition, AGC Pharma Chemicals’ award-winning efforts in sustainability, recognized with the EcoVadis Platinum rating, align with AbilityPharma’s commitment to responsible practices in drug development.
AGC Pharma Chemicals’ support goes beyond manufacturing. The company will provide comprehensive regulatory affairs assistance to manage the complex regulatory landscape associated with drug development and approval.
About AGC Pharma Chemicals
AGC Pharma Chemicals, based in Spain and Japan, responds to strong industry demand by focusing on its mission: to improve people’s lives through the highest quality products. The company is an innovative Contract Development and Manufacturing Organization (CDMO) working for the global pharmaceutical industry developing and manufacturing active pharmaceutical ingredients (APIs) and intermediates.
AGC Pharma Chemicals has experienced solid business growth and financial stability as part of the AGC Group, formerly known as Asahi Glass Company. The AGC Group is a global business conglomerate with over 190 companies, more than 56,700 employees and a presence in over 30 countries, with net sales of EUR 13,286 million (JPY152 = €1) during 2023.
About Ability Pharmaceuticals
AbilityPharma is a Catalan biotech company with a product called ABTL0812, currently in phase 2b clinical trials. Its focus is on improving the future of oncology by developing innovative therapies that address unmet medical needs. AbilityPharma is headquartered in
AbilityPharma is located in the Parc Tecnològic del Vallès (Cerdanyola del Vallès, Barcelona, Catalonia, Spain). Its current shareholders include the founders, private investors, Inveready, Fitalent, Innvierte (CDTI), SODENA, the EIC Fund and SciClone Pharmaceuticals. It also has the financial backing of ACCIO (Government of Catalonia), CDTI, ICO, ENISA, the Ministry of Science and Innovation (Government of Spain) and the European Commission (H2020 programme, European Innovation Council).
